Martin Treder
Fondateur chez LTZ Therapeutics, Inc.
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Ulrich Grau | M | 75 | 9 ans | |
| Bernhard R. M. Ehmer | M | 69 | 8 ans | |
| Robert Li | M | - |
LTZ Therapeutics, Inc.
 LTZ Therapeutics, Inc. BiotechnologyHealth Technology LTZ Therapeutics, Inc. is an American immunotherapy-focused biotech company that develops novel therapies. The company was founded by Jianhui Zhou, Robert Li, and Martin Treder, with Robert Li serving as the CEO since incorporation. | - |
| Jianhui Zhou | M | - |
LTZ Therapeutics, Inc.
LTZ Therapeutics, Inc. BiotechnologyHealth Technology LTZ Therapeutics, Inc. is an American immunotherapy-focused biotech company that develops novel therapies. The company was founded by Jianhui Zhou, Robert Li, and Martin Treder, with Robert Li serving as the CEO since incorporation. | - |
| Mathieu Simon | M | 68 | 6 ans | |
| Susanne Hering | F | - | 9 ans | |
| Wolfgang Fischer | M | 60 | 7 ans | |
| Denise Mueller | F | 55 | 8 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Caroline Y. Stewart | F | - | - | |
| Gregory W. Gin | M | - | - | |
| Irina Staatz-Granzer | M | 64 |
U3 Pharma AG
 U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | - |
| Anne Kerber | M | - | - | |
| Jean Deleage | M | 83 |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | 9 ans |
| Michael Wolf | M | - | - | |
| Oscar Kashala | M | - | - | |
| Andrew Curtis | M | - | - | |
| Jöerg Windisch | M | 53 | 1 ans | |
| Leila Alland | M | 61 | 1 ans | |
| Anca Alexandru | M | - | - | |
| Cassandra Choe-Juliak | M | - | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Allemagne | 18 | 90,00% |
| Etats-Unis | 2 | 10,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Martin Treder
- Réseau Personnel
